Información del artículo
Resumen
La Digestive Disease Week siempre ofrece novedades interesantes. Respecto de la enfermedad por reflujo gastroesofágico (ERGE), en 2012 destacaremos, entre otras novedades, los estudios sobre su relación con la dispepsia funcional. Asimismo, destacaremos nuevos datos que sugieren que realmente el reflujo no detectado tiene un papel en determinadas patologías extraesofágicas. También comentaremos la potencial utilidad de la impedanciometría de la mucosa esofágica para el diagnóstico de ERGE y revisaremos el manejo y las implicaciones de la falta de respuesta a los inhibidores de la bomba de protones. Respecto del esófago de Barrett revisaremos las prometedoras nuevas técnicas para el cribado del adenocarcinoma esofágico, y los nuevos datos sobre eficacia y durabilidad de la ablación mediante radiofrecuencia como tratamiento de elección para los casos asociados a displasia o neoplasia in situ.
Palabras clave:
Reflujo gastroesofágico
Esofagitis
Esófago de Barrett
Abstract
Digestive Disease Week always offers interesting advances. Among the notable advances concerning gastroesophageal reflux disease (GERD) in the 2012 meeting were studies on its association with functional dyspepsia. Furthermore, novel data suggest that undetected reflux plays a role in certain extraesophageal diseases. We also discuss the potential utility of impedanciometry of the esophageal mucosa in the diagnosis of GERD and review the management and implications of lack of response to proton pump inhibitors. We also review promising new techniques for screening for esophageal adenocarcinoma in Barrett's esophagus and new data on the efficacy and durability of radiofrequency ablation as the treatment of choice in cases associated with dysplasia or neoplasia in situ.
Keywords:
Gastro-esophageal reflux
Esophagitis
Barrett esophagus
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.M. Remes Troche, A.A. Azamar Jacome, A. Ramos-de la Medina, M. Torres-Aguilera, F.B. Roesch.
The Effects of carbonated and/or caffeinated beverages on acid and non-acid reflux and symptomatic perception among different phenotypes of GERD.
Gastroenterology, 142 (2012), pp. S286-S287
[2.]
T. Johnson, L. Gerson, T. Hershcovici, C. Stave, R. Fass.
Systematic review: the effects of carbonated beverages on gastrooesophagealreflux disease.
Aliment Pharmacol Ther, 31 (2010), pp. 607-614
[3.]
R.M. Lovell, A.C. Ford.
Prevalence of gastro-esophageal reflux disease in individuals with irritable bowel syndrome: a systematic review and meta-analysis.
Gastroenterology, 142 (2012), pp. S2
[4.]
R. Gadam, L.K. Jha, L. Nasrollah, R. Fass.
NAPS are more commonly associated with gastroesophageal reflux as compared with sleep time.
Gastroenterology, 142 (2012), pp. S167
[5.]
C.H. Wilder-Smith, A. Lussi.
Dental erosions in patients with silent gastro-oesophageal reflux disease (GERD): Characteristics and clinical course with proton pump inhibitor treatment.
Gastroenterology, 142 (2012), pp. S411
[6.]
J.O. Hayat, J.Y. Kang, P.W. Dettmar, A.T. Moore, L.C. Hicklin, E. Yazaki, et al.
Do patients with hoarseness and endoscopic signs of LPR have abnormal esophago-pharyngeal reflux?. A study using simultaneous impedance-phmetry, oro-pharyngeal pH monitoring (Restech) and pepsin measurements in saliva.
Gastroenterology, 142 (2012), pp. S411-S412
[7.]
D. Ummarino, L. Vandermeulen, B. Roosens, D. Urbain, B. Hauser, Y. Vandenplas.
Gastroesophageal reflux evaluation in adult patients affected by chronic cough: restech versus multichannel intraluminal impedance/pH metry.
Gastroenterology, 142 (2012), pp. S415
[8.]
G. Karamanolis, N. Viazis, K. Triantafyllou, D. Polymeros, J. Vlachogiannakos, D.G. Karamanolis, et al.
Could objective GERD parameters measured by impedance-pH predict response to PPIs in patients with non-cardiac chest pain?.
Gastroenterology, 142 (2012), pp. S419
[9.]
Fass R. Evaluation and therapy of non-cardiac chest pain [consultado 16-7-2012]. Disponible en: http://www.medscape.org/viewarticle/412800_3
[10.]
R. Farré, K. Blondeau, D. Clement, M. Vicario, L. Cardozo, M. Vieth, et al.
Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique.
Gut, 60 (2011), pp. 885-892
[11.]
N.A. Pardon, K. Blondeau, H. Vanheel, M. Vicario, T. Vanuytsel, A.V. Keita, et al.
In vivo and in vitro evaluation of esophageal mucosal integrity in healthy humans and GERD patients.
Gastroenterology, 142 (2012), pp. S146-S147
[12.]
P.W. Weijenborg, W.O. Rohof, L.M. Akkermans, P.D. Lundin, A.J. Smout, A.J. Bredenoord.
Esophageal electrical tissue impedance spectroscopy can detect esophageal permeability changes in gastroesophageal reflux disease during upper endoscopy.
Gastroenterology, 142 (2012), pp. S166-S167
[13.]
M.F. Vaezi, J. Mabary, T. Higginbotham, E.S. Yuksel, J.C. Slaughter.
A novel device measuring esophageal mucosal consequences of chronic GERD.
Gastroenterology, 142 (2012), pp. S167
[14.]
A. Kandulski, D. Kuester, C. Caro, J. Weigt, T. Wex, P. Malfertheiner.
Differentiation of gastroesophageal reflux disease (GERD) and functional heartburn (FH) by histopathological changes in patients with refractory heartburn.
Gastroenterology, 142 (2012), pp. S167
[15.]
N. Gupta, J.M. Inadomi, P. Sharma.
Effectiveness of proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD) in the general population: Results from a large population based AGA Survey.
Gastroenterology, 142 (2012), pp. S210
[16.]
N.B. Vakil, A. Niklasson, H. Denison, A. Rydén.
Symptom pattern in gastroesophageal reflux disease: Comparison with treatment naïve patients suggests overlapping disease entities in partial responders to proton pump inhibitor therapy.
Gastroenterology, 142 (2012), pp. S589-S590
[17.]
F. Zerbib, K. Belhocine, M. Simon, M. Capdepont, F. Mion, S. Bruley des Varannes, et al.
Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
Gut, 61 (2012), pp. 501-506
[18.]
D. Sifrim, F. Zerbib.
Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.
Gut, (2012),
[19.]
D. Jodorkovsky, J. Price, S. Dhalla, L. Musaib-Ali, E. Stein, J.O. Clarke.
Does the addition of multichannel intraluminal impedance (MII) to standard pH testing change clinical management in patients with gastroesophageal reflux disease (GERD)?.
Gastroenterology, 142 (2012), pp. S167-S168
[20.]
P.A. Naas, C. Rife, P. Nietert, D.O. Castell.
histamine receptor antagonists added to PPIs improve gastric acid control when taken chronically.
Gastroenterology, 142 (2012), pp. S86
[21.]
Y. Yamaji, H. Kambe, Y. Isomura, S. Yoshida, A. Yamada, Y. Hirata, et al.
Mosapride no sirve randomized controlled trial of efficacy of mosapride plus omeprazole versus omeprazole alone in therapy of gastroesophageal reflux disease.
Gastroenterology, 142 (2012), pp. S589
[22.]
N.B. Vakil, F.J. Huff, D. Bonzo, K.C. Cundy.
A dose-response efficacy and safety study of arbaclofen placarbil as adjunctive therapy in GERD patients who incompletely responded to PPI therapy.
Gastroenterology, 142 (2012), pp. S210
[23.]
B.F. Kessing, J.A. Broeders, N. Vinke, M.P. Schijven, E. Hazebroek, I.A. Broeders, et al.
Gas-related symptoms after anti-reflux surgery.
Gastroenterology, 142 (2012), pp. S584
[24.]
J.P. Galmiche, J. Hatlebakk, S. Attwood, C. Ell, R. Fiocca, S. Eklund, et al.
LOTUS Trial Collaborators Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial.
JAMA, 305 (2011), pp. 1969-1977
[25.]
D.F. Boerwinkel, W.L. Curvers, M.A. Kara, M. Visser, S.L. Meijer, J. Holz, et al.
Clinical impact of autofluorescence imaging on the endoscopic treatment for early barrett's neoplasia: a prospective assessment of 371 patients.
Gastroenterology, 142 (2012), pp. S748-S749
[26.]
D.F. Boerwinkel, J. Holz, M. Aalders, B.L. Weusten, M. Visser, J.J. Bergman.
First human feasibility study on third generation autofluorescence endoscopy for the detection of early neoplasia in barrett's esophagus.
Gastrointest Endosc, 75 (2012), pp. AB210
[27.]
R. Singh, W. Tam, M. Jayanna, N. Nordeen, B. George, G. Nind.
A preliminary feasibility study of using a novel narrow band imaging system with dual focus magnification capability in Barrett's oesophagus Is the time ripe to abandon random biopsies?.
Gastrointest Endosc, 75 (2012), pp. AB213-AB214
[28.]
A. Pacha, A.M. Rygiel, W. Westra, M.G. Dijkgraaf, M. Visser, J. Fiebo, et al.
Novel FISH biomarker assay detects barrett progressors: A phase IV five year prospective follow up study.
Gastroenterology, 142 (2012), pp. S445
[29.]
W.J. Bulsiewicz, A. Infantolino, C.J. Lightdale, A. Ertan, R.E. Pruitt, R. Muthusamy, et al.
The safety and efficacy of endoscopic mucosal resection prior to radiofrequency ablation for dysplastic Barrett's esophagus: results from the US RFA Registry.
Gastroenterology, 142 (2012), pp. S427
[30.]
M. Gupta, L.S. Lutzke, K.K. Wang, J.A. Abrams, T.C. Wang, C.J. Lightdale, et al.
Safety and outcomes of radiofrequency ablation for Barrett's esophagus in older subjects - Results from a BETRNet Consortium.
Gastrointest Endosc, 75 (2012), pp. AB159
[31.]
K.Y.N. Phoa, R.E. Pouw, R. Bisschops, O. Pech, K. Ragunath, B.L. Weusten, et al.
Radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia in 132 patients: Results of a prospective European multicenter study (Euro-II).
Gastrointest Endosc, 75 (2012), pp. AB159-AB160
[32.]
R.J. Haidry, J.M. Dunn, M.R. Banks, M.A. Butt, A. Gupta, G. Fullarton, et al.
HALO radiofrequency ablation for high grade dysplasia and early mucosal neoplasia arising in Barrett's oesophagus: Interim results form the UK HALO Radiofrequency Ablation Registry.
Gastroenterology, 142 (2012), pp. S745
[33.]
W.J. Bulsiewicz, H.P. Kim, C.C. Cotton, E.S. Dellon, S. Pasricha, R.D. Madanick, et al.
The safety of radiofrequency ablation (RFA) for treatment of neoplastic Barrett's esophagus (BE): A study of 244 patients with dysplasia or early cancer.
Gastroenterology, 142 (2012), pp. S751
[34.]
N.J. Shaheen, W.J. Bulsiewicz, R.I. Rothstein, S. Komanduri, H.C. Wolfsen, G. Triadafilopoulos, et al.
Radiofrequency ablation (RFA) safely treats Barrett's esophagus in a nationwide, multicenter cohort: Results from the US RFA Registry.
Gastroenterology, 142 (2012), pp. S752
[35.]
N.J. Shaheen, W.J. Bulsiewicz, R.I. Rothstein, S. Komanduri, H.C. Wolfsen, V.R. Muthusamy, et al.
Eradication rates of Barrett's esophagus using radiofrequency ablation (RFA): Results from the US RFA Registry.
Gastrointest Endosc, 75 (2012), pp. AB460
[36.]
S. Nurkin, H.R. Nava, S. Yendamuri, C.M. LeVea, C. Nwogu, G. Wilding, et al.
Outcomes of endoscopic resection for high grade dysplasia and esophageal cancer.
Gastrointest Endosc, 75 (2012), pp. AB473
[37.]
J. Lewis, C.R. Piraka, A.C. Chang, B.J. Elmunzer, R.S. Kwon, J.H. Rubenstein.
Comparison of esophagectomy vs. endoscopic mucosal resection for early neoplastic Barrett's esophagus.
Gastrointest Endosc, 75 (2012), pp. AB452-AB453
[38.]
C. Hur, S.U. Choi, J.H. Rubenstein, C.Y. Kong, D. Provenzale, N.S. Nishioka, et al.
The cost-effectiveness of radiofrequency ablation for Barrett's esophagus.
Gastroenterology, 142 (2012), pp. S73
[39.]
K.B. Dunbar, S.J. Spechler.
The risk of lymph node metastases in patients with high grade dysplasia or intramucosal carcinoma in Barrett's esophagus: A systematic review.
Gastroenterology, 142 (2012), pp. S72
[40.]
H.P. Kim, W.J. Bulsiewicz, C.C. Cotton, E.S. Dellon, R.D. Madanick, S. Pasricha, et al.
Endoscopic mucosal resection (EMR) prior to radiofrequency ablation (RFA) is equally effective and safe compared to RFA alone for the eradication of Barrett's esophagus (BE).
Gastrointest Endosc, 75 (2012), pp. AB461-AB462
[41.]
K.I. Ayers, C. Shi, K. Washington, P.S. Yachimski.
Combined expert histopathology review and endoscopic mucosal resection alters pre-treatment diagnosis in the majority of patients referred for endoscopic therapy of Barrett's esophagus-associated neoplasia.
Gastroenterology, 142 (2012), pp. S749
[42.]
E. Werbrouck, G. De Hertogh, X. Sagaert, H. Willekens, R. Bisschops.
Biopsies insufficiently predict final histology after endoscopic resection in Barrett's neoplasia.
Gastrointest Endosc, 75 (2012), pp. AB469-AB470
[43.]
B. Qumseya, C. Rizk, D.J. Cangemi, M. Raimondo, T.A. Woodward, et al.
Biopsy of Barrett's mucosa has a weak agreement with pathology from endoscopic mucosal resection of the same area.
Gastrointest Endosc, 75 (2012), pp. AB470
[44.]
F.G. Van Vilsteren, L. Álvarez Herrero, R.E. Pouw, K.Y.N. Phoa, C. Sondermeijer, G. Van Lijnschoten, et al.
Simplifying radiofrequency ablation of Barrett's esophagus: A randomized multicenter trial comparing three different treatment regimens for circumferential ablation using the HALO360 system.
Gastrointest Endosc, 75 (2012), pp. AB158
[45.]
F.G. Van Vilsteren, L. Álvarez Herrero, R.E. Pouw, K.Y.N. Phoa, C. Sondermeijer, M. Visser, et al.
A multicenter randomized trial comparing two ablation regimens for focal radiofrequency ablation of Barrett's mucosa using the HALO90 system.
Gastroenterology, 142 (2012), pp. S1038
[46.]
W.J. Bulsiewicz, C.J. Lightdale, R.E. Pruitt, G. Triadafilopoulos, W.D. Lyday, N.J. Shaheen.
Predictors of complete eradication of Barrett's esophagus by radiofrequency ablation (RFA) in a nationwide, multicenter cohort: Results from the US RFA Registry.
Gastroenterology, 142 (2012), pp. S3-S4
[47.]
F.G. Van Vilsteren, L. Álvarez Herrero, R.E. Pouw, D. Schrijnders, C. Sondermeijer, et al.
A prospective multicenter study to identify predictive markers for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia.
Gastrointest Endosc, 75 (2012), pp. AB158-AB159
[48.]
W.J. Bulsiewicz, H.P. Kim, C.C. Cotton, E.S. Dellon, S. Pasricha, R.D. Madanick, et al.
Predictors of ‘difficult to ablate’ Barrett's esophagus among 244 patients with dysplasia or early cancer.
Gastroenterology, 142 (2012), pp. S752
[49.]
M. Gupta, L.S. Lutzke, G.A. Prasad, T.C. Wang, J.A. Abrams, C.J. Lightdale, et al.
Recurrence of intestinal metaplasia after eradication of Barrett's esophagus with radio frequency ablation Results from a BETRNet Consortium.
Gastroenterology, 142 (2012), pp. S73
[50.]
H.P. Kim, W.J. Bulsiewicz, C.C. Cotton, E.S. Dellon, R.D. Madanick, N.J. Shaheen.
Durability of radiofrequency ablation (RFA) for eradication of dysplasia in Barrett's esophagus (BE) and risk factors for recurrent disease.
Gastrointest Endosc, 75 (2012), pp. AB289
[51.]
N. Gupta, S. Wani, T.G. Hollander, A.D. Higbee, B.J. Vaccaro, G. Balasubramanian, et al.
Recurrence of disease after endoscopic eradication therapy (Eet) for Barrett's esophagus (BE) with high grade dysplasia (HGD) and early cancer (EC).
Gastroenterology, 142 (2012), pp. S73
[52.]
K.Y.N. Phoa, R.E. Pouw, F.G. Van Vilsteren, C. Sondermeijer, F.J. Ten Kate, M. Visser, et al.
Prospective long-term follow-up after radiofrequency ablation for Barrett's esophagus with highgrade dysplasia and/or early cancer.
Gastrointest Endosc, 75 (2012), pp. AB449
[53.]
C. Zhou, T.-H. Tsai, H.-C. Lee, T. Kirtane, M. Figueiredo, Y.K. Tao, et al.
Identification and characterization of subsquamous intestinal metaplasia pre- and post-radiofrequency ablation using three-dimensional optical coherence tomography.
Gastroenterology, 142 (2012), pp. S336-S337
Copyright © 2012. Elsevier España, S.L.. Todos los derechos reservados
